Abstract
Self-antigens, in the form of differentiation antigens, are commonly recognized by the immune system on melanoma and other cancers. We have shown previously that active immunization of mice against the melanocyte differentiation antigen, a tyrosinase-related protein (TRP) gp75(TRP-1) (the brown locus protein) expressed by melanomas, could induce tumor immunity and autoimmunity manifested as depigmentation. In this system, tumor immunity and autoimmunity were mediated by autoantibodies. Here, we characterize immunity against another tyrosinase family glycoprotein TRP-2 (the slaty locus protein), using the same mouse model and method of immunization. As observed previously for gp75(TRP-1), immunity was induced by DNA immunization against a xenogeneic form of TRP-2, but not against the syngeneic gene, and depended on CD4(+) cells. Immunization against TRP-2 induced autoantibodies and autoreactive cytotoxic T cells. In contrast to immunization against gp75(TRP-1), both tumor immunity and autoimmunity required CD8(+) T cells, but not antibodies. Only autoimmunity required perforin, whereas tumor immunity proceeded in the absence of perforin. Thus, immunity induced against two closely related autoantigens that are highly conserved throughout vertebrate evolution involved qualitatively different mechanisms, i.e., antibody versus CD8(+) T cell. However, both pathways led to tumor immunity and identical phenotypic manifestations of autoimmunity.
MeSH Terms
Animals
Antibody Formation
Autoantibodies/immunology
Female
Humans
Immunotherapy
Intramolecular Oxidoreductases/genetics,immunology
Killer Cells, Natural/immunology
Lung Neoplasms/immunology,prevention & control,secondary
Lymphocyte Depletion
Melanoma, Experimental/immunology,pathology,prevention & control
Membrane Glycoproteins/deficiency,genetics,physiology
Mice
Mice, Inbred C57BL
Mice, Knockout
Neoplasm Transplantation
Perforin
Pore Forming Cytotoxic Proteins
T-Lymphocytes, Cytotoxic/immunology
Transfection
Transplantation, Heterologous
Transplantation, Isogeneic
Tumor Cells, Cultured
beta 2-Microglobulin/deficiency,genetics,physiology
Chemicals
Autoantibodies
Membrane Glycoproteins
Pore Forming Cytotoxic Proteins
beta 2-Microglobulin
Perforin
Intramolecular Oxidoreductases
dopachrome isomerase
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Bowne W B
Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Srinivasan R
Wolchok J D
Hawkins W G
Blachere N E
Dyall R
Lewis J J
Houghton A N
References (21)
21 references, click to expand
-
Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity.
Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14809-14
PMID: 8962137
-
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes.
J Exp Med. 1996 Dec 1;184(6):2207-16
PMID: 8976176
-
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma.
J Exp Med. 1997 Feb 3;185(3):453-9
PMID: 9053445
-
Melanosomal proteins as melanoma-specific immune targets.
Melanoma Res. 1997 Apr;7(2):83-95
PMID: 9167173
-
Fc receptors are required in passive and active immunity to melanoma.
Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):652-6
PMID: 9435247
-
Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33.
J Immunol. 1998 Jan 15;160(2):890-7
PMID: 9551926
-
B cells inhibit induction of T cell-dependent tumor immunity.
Nat Med. 1998 May;4(5):627-30
PMID: 9585241
-
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.
J Exp Med. 1998 Jul 20;188(2):277-86
PMID: 9670040
-
Tumor immunity and autoimmunity induced by immunization with homologous DNA.
J Clin Invest. 1998 Sep 15;102(6):1258-64
PMID: 9739060
-
Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2).
Cancer Res. 1998 Nov 1;58(21):4895-901
PMID: 9809996
-
Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
J Immunother Emphasis Tumor Immunol. 1996 Jan;19(1):81-4
PMID: 8859727
-
Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.
J Exp Med. 1995 Nov 1;182(5):1609-14
PMID: 7595233
-
Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.
Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9461-5
PMID: 7937789
-
Cancer antigens: immune recognition of self and altered self.
J Exp Med. 1994 Jul 1;180(1):1-4
PMID: 8006576
-
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2982-7
PMID: 10077623
-
Sequential chemoimmunotherapy in the treatment of metastatic melanoma.
J Clin Oncol. 1992 Aug;10(8):1338-43
PMID: 1634924
-
The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product.
J Exp Med. 1990 Apr 1;171(4):1375-80
PMID: 2324688
-
Prognostic significance of hypopigmentation in malignant melanoma.
Arch Dermatol. 1987 Aug;123(8):1053-5
PMID: 3631983
-
Vitiligo in patients with metastatic melanoma: a good prognostic sign.
J Am Acad Dermatol. 1983 Nov;9(5):689-96
PMID: 6643767
-
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.
J Exp Med. 1982 Dec 1;156(6):1755-66
PMID: 7175440
-
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.
J Exp Med. 1993 Aug 1;178(2):489-95
PMID: 8340755